Lys32
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Sumoylation Site Page: > Lys32  -  HIPK2 (human)

Site Information
FCSVKKLkIEPSSNW   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 1727700

In vivo Characterization
Methods used to characterize site in vivo:
electrophoretic mobility shift ( 2 , 4 ) , immunoassay ( 3 ) , mass spectrometry ( 1 ) , mutation of modification site ( 2 , 3 , 4 ) , western blotting ( 3 , 4 )
Disease tissue studied:
bone cancer ( 2 , 3 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Regulatory protein:
PIAS4 (human) ( 2 )
Treatments:
adriamycin ( 2 ) , SB203580 ( 2 )

Downstream Regulation
Effects of modification on HIPK2:
enzymatic activity, induced ( 2 ) , intracellular localization ( 2 ) , molecular association, regulation ( 3 ) , phosphorylation ( 2 ) , protein degradation ( 4 )
Effects of modification on biological processes:
transcription, induced ( 3 ) , transcription, inhibited ( 2 )
Inhibit interaction with:
TLE1 (human) ( 3 )

References 

1

Hendriks IA, et al. (2014) Uncovering global SUMOylation signaling networks in a site-specific manner. Nat Struct Mol Biol 21, 927-36
25218447   Curated Info

2

Roscic A, et al. (2006) Phosphorylation-dependent control of Pc2 SUMO E3 ligase activity by its substrate protein HIPK2. Mol Cell 24, 77-89
17018294   Curated Info

3

Sung KS, et al. (2005) Differential interactions of the homeodomain-interacting protein kinase 2 (HIPK2) by phosphorylation-dependent sumoylation. FEBS Lett 579, 3001-8
15896780   Curated Info

4

Gresko E, Möller A, Roscic A, Schmitz ML (2005) Covalent modification of human homeodomain interacting protein kinase 2 by SUMO-1 at lysine 25 affects its stability. Biochem Biophys Res Commun 329, 1293-9
15766567   Curated Info